| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 04/06/2011 | EP2305213A2 The treatment of small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions |
| 04/06/2011 | EP2305195A1 Drug delivery compositions for improved stability of steroids |
| 04/06/2011 | EP2305194A1 Sustained analgesia achieved with buprenorphine |
| 04/06/2011 | EP2305193A1 Sustained analgesia achieved with buprenorphine |
| 04/06/2011 | EP2305192A1 Sustained analgesia achieved with buprenorphine |
| 04/06/2011 | EP2305191A1 Sustained analgesia achieved with buprenorphine |
| 04/06/2011 | EP2304043A1 Hiv protease inhibitors and methods for using |
| 04/06/2011 | EP2303930A1 A sulfated polysaccharide compound and the preparation and use thereof |
| 04/06/2011 | EP2303924A2 Lm-antibodies, functional fragments, lm-1 target antigen, and methods for making and using same |
| 04/06/2011 | EP2303906A1 Crystalline polymorphs of gemcitabine base |
| 04/06/2011 | EP2303895A1 Thiazolyl- and oxazolyl-isoquinolinones and methods for using them |
| 04/06/2011 | EP2303894A1 Thiazolo [5, 4-b] pyridine and oxazolo [5, 4-b] pyridine derivatives as antibacterial agents |
| 04/06/2011 | EP2303893A1 Tricyclic indole derivatives and methods of use thereof |
| 04/06/2011 | EP2303891A1 Pyrazolo-quinazolines |
| 04/06/2011 | EP2303890A2 Phosphatidylinositol 3 kinase inhibitors |
| 04/06/2011 | EP2303889A1 Halo-substituted pyrimidodiazepines as plkl inhibitors |
| 04/06/2011 | EP2303888A2 Methods and compounds for antimicrobial intervention |
| 04/06/2011 | EP2303887A1 Alpha helix mimetics and methods relating thereto |
| 04/06/2011 | EP2303885A1 Process for producing bicycloaniline derivatives |
| 04/06/2011 | EP2303884A1 Adenine receptor ligands |
| 04/06/2011 | EP2303883A1 Purine derivatives further comprising a mercapto-acylamino group as neutral endopeptidase inhibitors |
| 04/06/2011 | EP2303882A2 Azacarboline derivatives, preparation method thereof and therapeutic use of same |
| 04/06/2011 | EP2303881A2 Fused heterocyclyc inhibitors of histone deacetylase and/or cyclin-dependent kinases |
| 04/06/2011 | EP2303880A2 Novel tricyclic derivatives, process for the preparation thereof and pharmaceutical compositions containing same |
| 04/06/2011 | EP2303879A1 7-azaindole derivatives |
| 04/06/2011 | EP2303878A1 Aza-indoles and related compounds having sphingosine-1-phosphate (s1p) receptor antagonist biological activity |
| 04/06/2011 | EP2303876A1 Diketo azolopiperidines and azolopiperazines as anti-hiv agents |
| 04/06/2011 | EP2303875A2 Compositions with and process for methylmorpholin-subsituted pyrido[2,3-d]pyrimidines |
| 04/06/2011 | EP2303873A1 Benzoxazinone derivatives acting as beta2-adrenoreceptor agonist for the treatment of respiratory disorders |
| 04/06/2011 | EP2303872A1 Isoxazole derivatives and their use as metabotropic glutamate receptor potentiators |
| 04/06/2011 | EP2303871A1 Pyrrolidin-3-ylmethyl-amine as orexin antagonists |
| 04/06/2011 | EP2303869A2 Process for the preparation of benzoimidazol-2-yl pyrimidine derivatives |
| 04/06/2011 | EP2303868A2 Stable r(+)-lansoprazole amine salt and a process for preparing the same |
| 04/06/2011 | EP2303867A1 Pyrazinone modulator of corticotropin-releasing factor receptor activity |
| 04/06/2011 | EP2303866A2 Crystalline forms of rabeprazole sodium |
| 04/06/2011 | EP2303863A1 5- and 6-membered heterocyclic compounds |
| 04/06/2011 | EP2303861A1 Pyridine compounds |
| 04/06/2011 | EP2303860A2 2-pyridyl substituted imidazoles as alk4 and/or alk4 inhibitors |
| 04/06/2011 | EP2303859A2 Aryl gpr119 agonists and uses thereof |
| 04/06/2011 | EP2303857A1 Cyclic sulfones with aminobenzyl substitution useful as bace inhibitors |
| 04/06/2011 | EP2303853A2 Novel salts and polymorphs of desazadesferrithiocin polyether analogues as metal chelation agents |
| 04/06/2011 | EP2303852A2 Inhibitors of akt activity |
| 04/06/2011 | EP2303851A1 Novel phenolic and catecholic amines and prodrugs thereof |
| 04/06/2011 | EP2303850A1 Novel potassium channel blockers and uses thereof |
| 04/06/2011 | EP2303849A1 Substituted quinazolines |
| 04/06/2011 | EP2303847A1 Synthesis of cyclic amidines |
| 04/06/2011 | EP2303846A1 Substituted isoquinolines and isoquinolinones as rho kinase inhibitors |
| 04/06/2011 | EP2303845A2 Bi-and polycyclic substituted isoquinoline and isoquinoline derivatives as rho kinase inhibitors |
| 04/06/2011 | EP2303844A1 Styrylquinolines, their process of preparation and their therapeutic uses |
| 04/06/2011 | EP2303842A1 A process for producing lercanidipine hc1 form v |
| 04/06/2011 | EP2303841A1 Oxindolyl inhibitor compounds |
| 04/06/2011 | EP2303840A2 Calcium ion channel modulators&uses thereof |
| 04/06/2011 | EP2303838A1 A new metformin glycinate salt for blood glucose control |
| 04/06/2011 | EP2303837A2 Novel compounds, use thereof as medicaments, and method for the preparation thereof |
| 04/06/2011 | EP2303836A1 Therapeutic cyclopentane derivatives |
| 04/06/2011 | EP2303832A1 Novel polymorphic forms of (4-{[(5-{[(3-chlorophenyl)methyl]oxy}-2-methylphenyl)carbonyl]amino}-3-methylphenyl)acetic acid |
| 04/06/2011 | EP2303831A2 Solid states of aliskiren free base |
| 04/06/2011 | EP2303830A1 Microbiological method for synthesizing cinnamoyl amide derivatives of amino acids |
| 04/06/2011 | EP2303823A1 Novel cinnamaldehyde derivatives having improved solubility in water, a method for preparing the same, a pharmaceutical composition comprising the same and a treatment method of cancer using the same |
| 04/06/2011 | EP2303407A1 Methods of detecting cells with a disrupted cell membrane, cells infected with a pathogen, dying cells or dead cells |
| 04/06/2011 | EP2303392A1 Pharmacokinetics of iontophoretic sumatriptan administration |
| 04/06/2011 | EP2303336A2 Sulfonylurea receptor and means for treating ischaemia |
| 04/06/2011 | EP2303330A1 Pharmaceutical compositions for treatment of parkinson's disease |
| 04/06/2011 | EP2303328A1 Water soluble curcumin compositions for use in anti-cancer and anti-inflammatory therapy |
| 04/06/2011 | EP2303325A2 Inhibition of emmprin to treat multiple sclerosis |
| 04/06/2011 | EP2303319A2 Compositions, methods and kits for eliciting an immune response |
| 04/06/2011 | EP2303301A2 Plant-based compositions and uses |
| 04/06/2011 | EP2303300A1 Compositions that aim to promote the development and growth of a beneficial vaginal microflora |
| 04/06/2011 | EP2303298A2 Compositions comprising extracts from boswellia serrata |
| 04/06/2011 | EP2303294A1 Probiotics to improve gut microbiota |
| 04/06/2011 | EP2303289A1 Mono ( iron hydroxypyrone ) and combination ( iron hydroxypyrone and gi inflammation inhibiting agents ) compositions for anaemia or h. pylori infections |
| 04/06/2011 | EP2303288A2 Conjugates of a polymer, a bisphosphonate and an anti-angiogenesis agent and uses thereof in the treatment and monitoring of bone related diseases |
| 04/06/2011 | EP2303287A1 Antiallergic marine biopolymers |
| 04/06/2011 | EP2303286A2 Compositions for inducing immune responses specific to globo h and ssea3 and uses thereof in cancer treatment |
| 04/06/2011 | EP2303285A2 Methods of making nucleoside tetraphosphate analogs |
| 04/06/2011 | EP2303284A2 Methods of treatment of bipolar disorder |
| 04/06/2011 | EP2303283A2 Anti-cancer combination therapy |
| 04/06/2011 | EP2303282A2 Treatment using continuous low dose application of sugar analogs |
| 04/06/2011 | EP2303281A1 Transdermal pharmaceutical compositions comprising danazol |
| 04/06/2011 | EP2303280A2 Compositions and methods for treatment of inflammation and hyperkeratotic lesions |
| 04/06/2011 | EP2303279A1 Topical steroidal formulations |
| 04/06/2011 | EP2303278A1 Composition for modulating stem cell growth with prostaglandins |
| 04/06/2011 | EP2303277A1 Inhibitors of akt activity |
| 04/06/2011 | EP2303276A1 Fumarate salt of 4- (3-chloro-2-fluoroanilino) -7-methoxy-6- { [1- (n-methylcarbamoylmethyl) piperidin- 4-yl]oxy}quinazoline |
| 04/06/2011 | EP2303275A2 Smoothened receptor modulators |
| 04/06/2011 | EP2303274A1 Multiple myeloma treatments |
| 04/06/2011 | EP2303273A1 Medical intervention in haematological cancers |
| 04/06/2011 | EP2303272A1 Sofinicline (abt-894 ) for attention-deficit/hyperactivity disorder |
| 04/06/2011 | EP2303271A1 Treatment of antibiotic-resistant bacteria infection |
| 04/06/2011 | EP2303270A1 Acylamino-substituted fused cyclopentanecarboxylic acid derivatives and their use as pharmaceuticals |
| 04/06/2011 | EP2303269A1 Inhibitors of akt activity |
| 04/06/2011 | EP2303268A1 Pharmaceutical compositions based on kinin b2 receptor antagonists and corticosteroids, and their use |
| 04/06/2011 | EP2303267A2 Polymorphic form of a [1, 2, 4] trizolo [4, 3-a! pyridine derivative for treating inflammatory diseases |
| 04/06/2011 | EP2303266A1 Pharmaceutical composition comprising a 4-hydroxy-2-oxo-2, 3- dihydro-1, 3-benzothiazol-7-yl compound for modulation of beta2-adrenoreceptor activity |
| 04/06/2011 | EP2303265A2 Stable topical formulation comprising voriconazole |
| 04/06/2011 | EP2303264A1 Methods of treating alpha adrenergic mediated conditions |
| 04/06/2011 | EP2303263A1 Use |
| 04/06/2011 | EP2303262A1 Dpp-iv inhibitors for use in the treatment of nafld |
| 04/06/2011 | EP2303261A1 Use of cyclolignans for the treatment of a hyperactive immune system |
| 04/06/2011 | EP2303260A1 Methods for determining sensitivity to aminoflavones |